Across TCGA pan-cancer cohorts, MIR323A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MIR323A data layer compared with 4 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher MIR323A Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR323A expression acts as an unfavorable survival marker.

SKCM, LUAD, and PRAD are the cancer types where MIR323A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	OS	Median	All	0.325	0.785	<.001	31	view →
LUAD	OS	Median	All	0.090	0.812	<.001	24	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MIR323A tumor-vs-normal RNA expression · all MIR323A data types